China STudy of valsartan/amlodipine fixed-dose combination-bAsed long-Term blood pressUre management in HypertenSive patients: a one-year registry (China STATUS III)

References

• Lim SS, Vos T, Flaxman AD, et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380:2224–2260.
   PubMed Web of Science ®Google Scholar
• Mozaffarian D, Benjamin EJ, Go AS, et al. American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics – 2015 update: a report from the American Heart Association. Circulation. 2015;131:e29–322.
   PubMed Web of Science ®Google Scholar
• Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2013;31:1281–1357.
   PubMed Web of Science ®Google Scholar
• Hu L, Huang X, You C, et al. Prevalence and risk factors of prehypertension and hypertension in Southern China. PLoS One. 2017;12:e0170238
   PubMed Web of Science ®Google Scholar
• Wang J, Zhang L, Wang F, et al. Prevalence, awareness, treatment, and control of hypertension in China: results from a national survey. Am J Hypertens. 2014;27:1355–1361.
   PubMed Web of Science ®Google Scholar
• Yang G, Wang Y, Zeng Y, et al. Rapid health transition in China, 1990–2010: findings from the Global Burden of Disease Study 2010. Lancet. 2013;381:1987–2015.
   PubMed Web of Science ®Google Scholar
• Commission CHaFP. China Health and Family Planning Statistical Yearbook. Beijing (China): China Union Medical University Press; 2015.
   Google Scholar
• Li J, Shi L, Li S, et al. Urban-rural disparities in hypertension prevalence, detection, and medication use among Chinese Adults from 1993 to 2011. Int J Equity Health. 2017;16:50.
   PubMed Web of Science ®Google Scholar
• Wang Z, Chen Z, Zhang L, et al. Status of hypertension in China: results from the China Hypertension Survey, 2012–2015. Circulation. 2018;137:2344–2356.
   PubMed Web of Science ®Google Scholar
• Cao Q, Pei P, Zhang J, et al. Hypertension unawareness among Chinese patients with first-ever stroke. BMC Public Health. 2016;16:170.
   PubMed Web of Science ®Google Scholar
• Sison J, Assaad-Khalil SH, Najem R, et al. Real-world clinical experience of amlodipine/valsartan and amlodipine/valsartan/hydrochlorothiazide in hypertension: the EXCITE study. Curr Med Res Opin. 2014;30:1937–1945.
   PubMed Web of Science ®Google Scholar
• Pereira M, Lunet N, Azevedo A, et al. Differences in prevalence, awareness, treatment and control of hypertension between developing and developed countries. J Hypertens. 2009;27:963–975.
   PubMed Web of Science ®Google Scholar
• Chiang CE, Wang TD, Li YH, et al. 2010 guidelines of the Taiwan Society of Cardiology for the management of hypertension. J Formos Med Assoc. 2010;109:740–773.
   PubMed Web of Science ®Google Scholar
• Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating Committee. Hypertension. 2003;42:1206–1252.
   PubMed Web of Science ®Google Scholar
• Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC practice guidelines for the management of arterial hypertension. Blood Press. 2014;23:3–16.
   PubMed Web of Science ®Google Scholar
• Huang J, Sun NL, Hao YM, et al. Efficacy and tolerability of a single-pill combination of amlodipine/valsartan in Asian hypertensive patients not adequately controlled with valsartan monotherapy. Clin Exp Hypertens. 2011;33:179–186.
   PubMed Web of Science ®Google Scholar
• Philipp T, Smith TR, Glazer R, et al. Two multicenter, 8-week, randomized, double-blind, placebo-controlled, parallel-group studies evaluating the efficacy and tolerability of amlodipine and valsartan in combination and as monotherapy in adult patients with mild to moderate essential hypertension. Clin Ther. 2007;29:563–580.
   PubMed Web of Science ®Google Scholar
• Schrader J, Salvetti A, Calvo C, et al. The combination of amlodipine/valsartan 5/160 mg produces less peripheral oedema than amlodipine 10 mg in hypertensive patients not adequately controlled with amlodipine 5 mg. Int J Clin Pract. 2009;63:217–225.
   PubMed Web of Science ®Google Scholar
• Sica DA. Rationale for fixed-dose combinations in the treatment of hypertension: the cycle repeats. Drugs. 2002;62:443–462.
   PubMed Web of Science ®Google Scholar
• Whelton PK, Carey RM, Aronow WS, et al. ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines. J Am Coll Cardiol. 2018;71:e127–248.
   Web of Science ®Google Scholar
• ESH/ESC Task Force for the Management of Arterial Hypertension. 2013 Practice guidelines for the management of arterial hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC): ESH/ESC Task Force for the Management of Arterial Hypertension. J Hypertens. 2013;31:1925–1938.
   PubMed Web of Science ®Google Scholar
• Hu D, Liu L, Li W. Efficacy and safety of valsartan/amlodipine single-pill combination in 11,422 Chinese patients with hypertension: an observational study. Adv Ther. 2014;31:762–775.
   PubMed Web of Science ®Google Scholar
• Wang JG, Zeng WF, He YS, et al. Valsartan/amlodipine compared to nifedipine GITS in patients with hypertension inadequately controlled by monotherapy. Adv Ther. 2013;30:771–783.
   PubMed Web of Science ®Google Scholar
• James PA, Oparil S, Carter BL, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014;311:507–520.
   PubMed Web of Science ®Google Scholar
• Liu LS. [2010 Chinese guidelines for the management of hypertension]. Zhonghua Xin Xue Guan Bing Za Zhi. 2011;39:579–615.
   PubMedGoogle Scholar
• Ke Y, Zhu D, Hong H, et al. Efficacy and safety of a single-pill combination of amlodipine/valsartan in Asian hypertensive patients inadequately controlled with amlodipine monotherapy. Curr Med Res Opin. 2010;26:1705–1713.
   PubMed Web of Science ®Google Scholar
• Ke YN, Huang J, Zhu JR. 缬沙坦／氨氯地平复方片剂对单药控制不良的轻中度高血压患者的疗效观察 [Efficacy and safety of the single pill combination of valsartan 80 mg plus amlodipine 5 mg in mild to moderate essential hypertensive patients without adequate blood pressure control by monotherapy]. Zhonghua Xin Xue Guan Bing Za Zhi. 2009;37:794–799. Chinese.
   PubMedGoogle Scholar
• Zhu D, Yang K, Sun N, et al. Amlodipine/valsartan 5/160 mg versus valsartan 160 mg in Chinese hypertensives. Int J Cardiol. 2013;167:2024–2030.
   PubMed Web of Science ®Google Scholar
• Philipp T, Glazer RD, Zhao Y, et al. Long-term tolerability and efficacy of the combination of amlodipine/valsartan in hypertensive patients: a 54-week, open-label extension study. Curr Med Res Opin. 2009;25:187–193.
   PubMed Web of Science ®Google Scholar
• Smith TR, Glazer RD, Koren MJ, et al. Combination therapy with amlodipine/valsartan in essential hypertension: a 52-week, randomised, open-label, extension study. Int J Clin Pract. 2010;64:1367–1374.
   PubMed Web of Science ®Google Scholar
• Allemann Y, Fraile B, Lambert M, et al. Efficacy of the combination of amlodipine and valsartan in patients with hypertension uncontrolled with previous monotherapy: the Exforge in Failure after Single Therapy (EX-FAST) study. J Clin Hypertension. 2008;10:185–194.
   PubMed Web of Science ®Google Scholar
• Karpov Y, Dongre N, Vigdorchik A, et al. Amlodipine/valsartan single-pill combination: a prospective, observational evaluation of the real-life safety and effectiveness in the routine treatment of hypertension. Adv Therapy. 2012;29:134–147.
   PubMed Web of Science ®Google Scholar
• Burnier M. Drug adherence in hypertension. Pharmacol Res. 2017;125:142–149.
   PubMed Web of Science ®Google Scholar
• Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. 2018;71:1269–1324.
   PubMed Web of Science ®Google Scholar
• Lu J, Lu Y, Wang X, et al. Prevalence, awareness, treatment, and control of hypertension in China: data from 1.7 million adults in a population-based screening study (China PEACE Million Persons Project). Lancet. 2017;390:2549–2558.
   PubMed Web of Science ®Google Scholar
• Su M, Zhang Q, Bai X, et al. Availability, cost, and prescription patterns of antihypertensive medications in primary health care in China: a nationwide cross-sectional survey. Lancet. 2017;390:2559–2568.
   Google Scholar
• Ma C. A cross-sectional survey of medication adherence and associated factors for rural patients with hypertension. Appl Nurs Res. 2016;31:94–99.
   PubMed Web of Science ®Google Scholar
• Erdine S. Compliance with the treatment of hypertension: the potential of combination therapy. J Clin Hypertens. 2010;12:40–46.
   PubMed Web of Science ®Google Scholar
• Elliott WJ. Improving outcomes in hypertensive patients: focus on adherence and persistence with antihypertensive therapy. J Clin Hypertens. 2009;11:376–382.
   PubMed Web of Science ®Google Scholar
• Chang J, Yang W, Fellers T, et al. Chart review of patients on valsartan-based single-pill combinations vs. ARB-based free combinations for BP goal achievement. Curr Med Res Opin. 2010;26:2203–2212.
   PubMed Web of Science ®Google Scholar
• Frampton JE, Scott LJ. Amlodipine/valsartan single-pill combination: a review of its use in the management of hypertension. Am J Cardiovasc Drugs. 2009;9:309–330.
   PubMed Web of Science ®Google Scholar
• Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353:487–497.
   PubMed Web of Science ®Google Scholar
• Parati G, Ochoa JE, Bilo G. Home blood pressure monitoring in hypertension. In: Berbari A, Mancia G (editors). Special Issues in Hypertension. Italy: Springer; 2012. p. 103–120.
   Google Scholar
• Nasothimiou EG, Tzamouranis D, Rarra V, et al. Diagnostic accuracy of home vs. ambulatory blood pressure monitoring in untreated and treated hypertension. Hypertens Res. 2012;35:750–755.
   PubMed Web of Science ®Google Scholar
• Niiranen TJ, Hanninen MR, Johansson J, et al. Home-measured blood pressure is a stronger predictor of cardiovascular risk than office blood pressure: the Finn-Home study. Hypertension. 2010;55:1346–1351.
   PubMed Web of Science ®Google Scholar
• Miura S, Saku K. Efficacy and safety of angiotensin II type 1 receptor blocker/calcium channel blocker combination therapy for hypertension: focus on a single-pill fixed-dose combination of valsartan and amlodipine. J Int Med Res. 2012;40:1–9.
   PubMed Web of Science ®Google Scholar
• Kafrawy NE, Rashwan M, Lion K, et al. Effectiveness and tolerability of fixed dose combination of amlodipine/valsartan in treatment of hypertension in the real-life setting among Egyptian patients. Egypt Heart J. 2014;66:30–35.
   Google Scholar